Tirzepatide for Weight Loss Maintenance Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial, Lancet (2026) [PubMed abstract] BIBLIOGRAPHY 1 - Zepbound PI 2 - PMID 34170647 - Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes, NEJM (2021) 3 - PMID 35133415 - Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial, JAMA (2022) 4 - North Carolina Pharmacy Practice Act
This genetic context, interpreted with your provider, can support a more informed conversation about your expected dose range and potential side effect sensitivity, though genetics does not predict your exact semaglutide response
Speak with your healthcare provider about strategies to minimise these effects, such as taking the medication correctly (on an empty stomach with no more than 120ml of plain water, swallowing the tablet whole without splitting, crushing or chewing, and waiting at least 30 minutes before eating, drinking or taking other oral medicines)
3 Results 3.1 Protective effect of CGA on cells CGA is a condensed phenolic acid formed by caffeic acid and quinic acid, with the chemical formula C16H18O9 (Figure 1A) and CAS number 327-97-9
